Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 20, 2016 01:18 ET | Source: Basilea Pharmaceutica Ltd.

Basilea announces distribution agreement with Unimedic for CRESEMBA(R) (isavuconazole) and Zevtera(R) (ceftobiprole) in the Nordic countries

BASEL, Switzerland, Sept. 20, 2016 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that Basilea Pharmaceutica International Ltd. (Basilea) has entered into a license and...
September 13, 2016 01:24 ET | Source: Basilea Pharmaceutica Ltd.

Basilea announces supply, distribution and license agreement with Grupo Biotoscana for CRESEMBA(R) (isavuconazole) and Zevtera(R) (ceftobiprole) in Latin America

BASEL, Switzerland, Sept. 13, 2016 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that Basilea Pharmaceutica International Ltd. (Basilea) has entered into a supply,...
August 17, 2016 01:19 ET | Source: Basilea Pharmaceutica Ltd.

Basilea announces distribution agreement with Hikma for CRESEMBA(r) (isavuconazole) in the MENA region

Basilea extending its agreement with Hikma to include antifungal CRESEMBA ® in addition to antibiotic Zevtera ® BASEL, Switzerland, Aug. 17, 2016 (GLOBE NEWSWIRE) -- Basilea...
August 15, 2016 01:33 ET | Source: Basilea Pharmaceutica Ltd.

Basilea reports 2016 half-year results - CRESEMBA(R) launched in key European markets

Antifungal CRESEMBA® (isavuconazole) launched in first European markets Entered contract with BARDA for the development and potential US registration of the antibiotic ceftobiprole...
June 27, 2016 01:22 ET | Source: Basilea Pharmaceutica Ltd.

Basilea's antifungal CRESEMBA(r) (isavuconazole) launched in Italy

BASEL, Switzerland, June 27, 2016 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) announces that it has launched its new azole antifungal CRESEMBA® (isavuconazole) in Italy and will...
March 09, 2016 01:19 ET | Source: Basilea Pharmaceutica Ltd.

Basilea announces that The Lancet Infectious Diseases published results from the CRESEMBA(R) (isavuconazole) open-label study for the treatment of mucormycosis

BASEL, Switzerland, March 9, 2016 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that results from the open-label phase 3 VITAL study evaluating CRESEMBA®...
March 04, 2016 01:18 ET | Source: Basilea Pharmaceutica Ltd.

Basilea launching antifungal CRESEMBA(R) (isavuconazole) in Germany

BASEL, Switzerland, March 4, 2016 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) hosts a symposium to support the launch of the new azole antifungal CRESEMBA® (isavuconazole) in...
March 03, 2016 01:21 ET | Source: Basilea Pharmaceutica Ltd.

Basilea launching antifungal CRESEMBA(r) (isavuconazole) in the United Kingdom

BASEL, Switzerland, March 3, 2016 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) hosts a symposium to support the launch of the new azole antifungal CRESEMBA® (isavuconazole) in the...
February 29, 2016 01:22 ET | Source: Basilea Pharmaceutica Ltd.

Basilea reports solid 2015 full-year results and is launching CRESEMBA(r), its second hospital anti-infective, in Europe

CRESEMBA® approval in U.S. and Europe and launched in the U.S. by Astellas Zevtera® launched in major European countries Tumor checkpoint controller BAL101553 interim phase 2a...
October 16, 2015 10:55 ET | Source: Basilea Pharmaceutica Ltd.

Basilea announces that European Commission approves isavuconazole (CRESEMBA(r)) as a treatment for invasive aspergillosis and mucormycosis in the European Union

Basilea's second anti-infective product approved in Europe, providing potential commercial synergy with Zevtera® (ceftobiprole) BASEL, Switzerland, Oct. 16, 2015 (GLOBE NEWSWIRE) -- Basilea...